Press Release

View printer-friendly version

<<  Back

Geron Grants License to Asia Biotech Corporation

Commercial License to Develop and Market Non–Therapeutic Products Using Telomerase Activators

MENLO PARK, Calif., March 12, 2007 – Geron Corporation (Nasdaq: GERN) today announced it has granted an exclusive global license to Asia Biotech Corporation for the development of non–prescription dietary food supplements, nutraceuticals and cosmetics containing Geron’s small molecule telomerase activating compounds. Terms of the license were not disclosed.

About Asia Biotech Corporation
Asia Biotech Corporation is a privately held company that will market products under the license through a wholly owned subsidiary, Telomerase Activation Sciences, which is headquartered in New York. For more information, visit www.TASciences.com.

About Geron Corporation
Geron is a biopharmaceutical company developing therapeutic products for cancer, cell–based therapies using human embryonic stem cell technology, and drug therapies to address senescence related diseases and conditions using its telomerase activating compounds. In 2005, Geron formed TA Therapeutics Limited in Hong Kong to develop the compounds for therapeutic use.

This news release may contain forward–looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward–looking statements in this press release regarding Geron’s intellectual property rights constitute forward–looking statements involving risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, need for additional capital, reliance on collaborators, need for regulatory approvals or clearances, and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward–looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Geron’s periodic reports, including the quarterly report on Form 10–Q for the quarter ended Sept. 30, 2006.

CONTACTS:

Media: David Schull, Noonan Russo, 858–546–4810, david.schull@eurorscg.com

Investors: Matthew Haines, Noonan Russo, 212–845–4235, matthew.haines@eurorscg.com

At Geron: David L. Greenwood, Chief Financial Officer, 650–473–7765, info@geron.com

# # #